Molecular profiling is rather likely to be cost effective

In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.